Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03046836
Other study ID # 54689
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 1, 2017
Est. completion date April 11, 2021

Study information

Verified date May 2022
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alcohol use disorders (AUD) and intimate partner aggression (IPA) frequently co-occur. There are significant health and economic burdens associated with AUD and co-occurring IPA, and little empirical data to guide treatment efforts. The neuropeptide oxytocin may help mitigate both AUD and IPA. However, clinical data examining oxytocin's effects on human aggression is scant. The proposed study is designed to address these gaps in the literature by utilizing a human laboratory paradigm to test the effects of oxytocin on craving and aggression among couples with AUD and co-occurring IPA.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date April 11, 2021
Est. primary completion date April 11, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Inclusion criteria indicate that participants must - aged 18 or over - fluent in English - endorse at least one instance of mild or moderate physical IPA with their partner in the past 6 months as defined by the Revised Conflict Tactics Scale (CTS-2) - both partners must be willing to participate - one or both partners must meet Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for an alcohol use disorder (AUD). Concurrent substance use disorders (e.g., marijuana) is acceptable provided alcohol is the participant's primary substance of choice. Exclusion Criteria: - Exclusion criteria include - pregnancy or breastfeeding - current or history of psychiatric or medical condition that could interfere with neuroendocrine function (e.g., hematological, endocrine, renal, or pulmonary disease; synthetic glucocorticoid or exogenous steroid therapy; psychotic, bipolar, eating disorders) - Body Max Index (BMI) = 39 - current suicidal ideation and intent - severe physical or sexual IPA in the past six months as defined by the Conflict Tactics Scale (CTS-2) - initiation of psychotropic medication in the past 4 weeks - acute alcohol withdrawal as indicated by a score of 8 or greater on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxytocin
40 IU oxytocin nasal spray
Placebo
Saline

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (1)

Lead Sponsor Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Alcohol Craving Change in subjective alcohol craving as measured by a Visual Analogue Scale (VAS) between time point 3 (before the alcohol cue) and 4 (after the alcohol cue).
Participants completed the VAS at 8 timepoints:
Minute 0 (pre-OT/placebo) (Time 1) Minute 5 (pre-OT/placebo) (Time 2) OT/placebo administered at minute 10 Minute 40 (Time 3) Minute 45 - alcohol cue paradigm began Time 4 (immediately after alcohol cue) Minute 65 - TAP began Time 5 (immediately after TAP began) Time 6 (15 minutes after TAP) Time 7 (30 minutes after TAP) Time 8 (60 minutes after TAP)
This 100mm Visual Analogue Scale (VAS) was anchored on a 100mm Likert-type scale from 0 (not at all/no craving) to 10 (extremely/maximum carving). The scale is set to 100mm in length, and the lowest value is a 0 (zero), representing no craving and and highest value is a 10 (ten) representing extreme craving.
Participants completed the VAS at 8 timepoints. Outcome measure represents the change in VAS scores between time point 3 (before the alcohol cue) and 4 (after the alcohol cue).
Primary Laboratory Intimate Partner Aggression Intensity (IPA) Intensity of laboratory-based IPA was assessed using the Taylor Aggression Paradigm (TAP). IPA intensity is operationalized as the volume of "shock" administered on a 1-10 (1 is least intense, 10 is most intense) scale using the computer based paradigm in response to "losing" trials.
TAP is a fictitious reaction time competition among partners. Participants are told that a winning trial required them to deliver a shock to their partner that ranged from 1 to 10 intensity for a duration of their choosing. A losing trial resulted in them receiving a shock from their partner (administered through two electrodes attached to the index and middle fingers of the nondominant hand). In reality, all participants received an identical sequence of "winning" or "losing" trials (and corresponding shocks) generated by the TAP software. IPA was operationalized as the average intensity (volume) and duration of shocks administered in response to "losing" trials.
10 minutes from start to end of TAP
Primary Laboratory Intimate Partner Aggression (IPA) Duration Laboratory IPA Duration was measured by the length of time participants administered "shocks" in the Taylor Aggression Paradigm (TAP). Measured in milliseconds. Greater number of milliseconds represents a longer shock.
TAP is a fictitious reaction time competition among partners. Participants are told that a winning trial required them to deliver a shock to their partner that ranged from 1 to 10 intensity for a duration of their choosing. A losing trial resulted in them receiving a shock from their partner (administered through two electrodes attached to the index and middle fingers of the nondominant hand). In reality, all participants received an identical sequence of "winning" or "losing" trials (and corresponding shocks) generated by the TAP software. IPA was operationalized as the average intensity (volume) and duration of shocks administered in response to "losing" trials.
10 minutes from start to end of TAP
Secondary Change in Cortisol Change in salivary cortisol measured between Time 4 (before the laboratory aggression paradigm) and Time 5 (after the laboratory aggression paradigm).
Participants completed the VAS at 8 timepoints:
Minute 0 (pre-OT/placebo) (Time 1) Minute 5 (pre-OT/placebo) (Time 2) OT/placebo administered at minute 10 Minute 40 (Time 3) Minute 45 - alcohol cue paradigm began Time 4 (immediately after alcohol cue) Minute 65 - TAP began Time 5 (immediately after TAP began) Time 6 (15 minutes after TAP) Time 7 (30 minutes after TAP) Time 8 (60 minutes after TAP)
Higher salivary cortisol is indicative of higher stress response and lower salivary cortisol is indicative of lower stress response.
Measured between Time 4 (before the laboratory aggression paradigm) and Time 5 (after the laboratory aggression paradigm).
Secondary Change in Subjective Aggression Mean change in subjective aggression scores as measured by a Visual Analogue Scale (VAS) between time point 4 (after alcohol cue) and 5 (during Taylor Aggression Paradigm, TAP).
Participants completed the VAS at 8 timepoints:
Minute 0 (pre-OT/placebo) (Time 1) Minute 5 (pre-OT/placebo) (Time 2) OT/placebo administered at minute 10 Minute 40 (Time 3) Minute 45 - alcohol cue paradigm began Time 4 (immediately after alcohol cue) Minute 65 - TAP began Time 5 (immediately after TAP began) Time 6 (15 minutes after TAP) Time 7 (30 minutes after TAP) Time 8 (60 minutes after TAP)
This 100mm Visual Analogue Scale (VAS) was anchored on a Likert-type scale from 0 (not at all/no aggression) to 10 (extremely/maximum aggression). The scale is set to 100mm in length, and the lowest value is a 0 (zero), representing no aggression and and highest value is a 10 (ten) representing extreme aggression.
Change is aggression measured between time point 4 (after the alcohol cue) and 5 (during Taylor Aggression Paradigm).
See also
  Status Clinical Trial Phase
Completed NCT05606601 - An Online Intervention Addressing Mental Health and Substance Use in University Students N/A
Completed NCT01668992 - Impact Evaluation of a Family-based Intervention With Burmese Migrant and Displaced Children and Families in Tak Province, Thailand N/A
Completed NCT01679236 - Pilot Study on Mindfulness for Tobacco and Alcohol in University Students Phase 0
Completed NCT00237003 - A Brief Alcohol Intervention for Incarcerated Women Phase 3
Withdrawn NCT00914719 - Alcohol Use and Sexual Risk: An Intervention N/A
Terminated NCT05274217 - Journey of Transformation Curriculum for Native American Adolescents N/A
Completed NCT05372042 - CBT Texts for PTSD & Hazardous Drinking (Project Better) N/A
Completed NCT03855410 - Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention N/A
Completed NCT01970293 - AA Linkage for Alcohol Abusing Women Leaving Jail N/A
Completed NCT01934803 - Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort N/A
Completed NCT01694082 - Brief Web-Based Alcohol Reduction Intervention for Undergraduates N/A
Completed NCT00247182 - Stepped Care for Mandated College Students Phase 1
Completed NCT00249496 - Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1 N/A
Withdrawn NCT03938077 - A Community-University Approach to Preventing HIV N/A
Recruiting NCT06124898 - Multi-Component Breath Alcohol Intervention N/A
Completed NCT02938377 - Alcohol Research Consortium in HIV-Intervention Research Arm Phase 4
Recruiting NCT05087875 - Evaluating an mHealth Intervention for Reducing Alcohol Use Among Rural Adolescent and Young Adult Cancer Survivors N/A
Completed NCT02963818 - Smartphone Technology: Young Adult Drinking Phase 1/Phase 2
Completed NCT02530645 - Development and Testing of a Smartphone Application to Reduce Substance Use and Sexual Risk Among Homeless Young Adults N/A
Completed NCT01614626 - Alcohol's Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort